Establishing a Risk Model for Diabetic Nephropathy
Introduction
This study aims to create a model that predicts the risk of diabetic nephropathy (DN) in patients with type 2 diabetes. It also examines the effects of combining Epalrestat with Dapagliflozin for treating DN.
Methods
The study had two phases:
- Phase I: Analyzed data from 460 patients who had kidney biopsies between June 2018 and June 2021. They were split into two groups to develop a predictive model using logistic regression.
- Phase II: Involved 94 DN patients treated from January 2022 to August 2023. They were divided into a control group (47 patients on Dapagliflozin) and a research group (47 patients on Epalrestat plus Dapagliflozin). The study compared their glucose levels, kidney function, and safety of treatments.
Results
The risk model from Phase I effectively diagnosed DN and assessed risks, providing useful insights for clinical practice. In Phase II, the research group showed improved glucose metabolism and kidney function compared to the control group after treatment (P < .05). However, both groups had similar rates of adverse reactions (P > .05).
Conclusion
The combination of Epalrestat and Dapagliflozin is effective in treating DN, significantly enhancing glucose metabolism and kidney function in patients.
Value of Clinical Trials
Clinical trials are essential for developing safe and effective treatments. It’s vital to integrate their findings into everyday medical practice. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into a single, user-friendly resource for clinicians.
Practical Solutions for Healthcare
In today’s healthcare landscape, efficiency is key. Our mobile apps facilitate scheduling, treatment monitoring, and telemedicine, simplifying patient care and expanding digital services.
By leveraging AI, clinics can streamline workflows, improve patient outcomes, and reduce paperwork. Discover how we can assist you at aidevmd.com.
